Medical System Network (4350) · RiskDropped
Earnings pressure from the normalization of transaction volumes for hepatitis C treatments
First written in FY2017. 1 of 2 entries say "Materialised", first in FY2017. Latest entry: FY2018.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Declining pharmaceutical wholesaling revenue due to contraction of the hepatitis C treatment marketA theme 3 companies write about · 3 as a headwind · 0 as a tailwind
0 other companies' latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2018DroppedAnnual reportThe normalization of transaction volumes for hepatitis C treatments was not reiterated as a factor putting downward pressure on earnings in the explanation of results and business risks for the consolidated fiscal year.
- FY2017MaterialisedAnnual report
「Revenue was ¥3,237 million, up 0.0% year on year, and operating profit was ¥1,718 million, down 3.3%, due to the normalization of transaction volumes for hepatitis C treatments, sluggish system sales, and depreciation expenses arising from the development of the core system.」
The normalization of transaction volumes for hepatitis C treatments emerged in the full-year results as a factor suppressing growth in revenue and profit in the pharmaceutical and other network business.